AMD hits multi-year highs on surprise Q2 profit >>> READ MORE

5 Stocks Leading the Generic Drug Charge

Between legislation and a wave of patent expiration, these pharmaceuticals are sitting pretty

      View All  

Teva Pharmaceutical

TEVAMost would hail Teva Pharmaceutical (TEVA) as the king of the generic drug world, not just because it’s one of the biggest, but also because it’s one of the best, with more than 350 generic drugs under its umbrella, and a few non-generics as well.

Despite the recent ruling that one of its top-selling drugs — copaxone, a treatment for multiple sclerosis — wouldn’t be able to extend its patent until 2015 (allowing generic versions of the same drug as early as 2014), the impact of that looming sales drop has been more than baked into the stock’s current price.

Again, even though copaxone makes up about a fifth of the company’s revenue, Teva has 350 generics generating sales; the company has proven it knows how to acquire, develop, or partner its way into new solid revenue-bearing pharmaceuticals.

Article printed from InvestorPlace Media,

©2017 InvestorPlace Media, LLC